{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Salgado BB"],"funding":["São Paulo Research Foundation","WHO by the COVID-19 Solidarity Response Fund and the German Federal Ministry of Health (BMG)","WHO Unity Studies","National Council for Scientific and Technological Development","ILMD/Fiocruz Amazônia","Fundo de Apoio ao Ensino, Pesquisa e Extensão from UNICAMP","Fundação de Amparo à Pesquisa do Estado do Amazonas","Inova Fiocruz/Fundação Oswaldo Cruz grant"],"pagination":["1018"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10143282"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["15(4)"],"pubmed_abstract":["Numerous studies have focused on inflammation-related markers to understand COVID-19. In this study, we performed a comparative analysis of spike (S) and nucleocapsid (N) protein-specific IgA, total IgG and IgG subclass response in COVID-19 patients and compared this to their disease outcome. We observed that the SARS-CoV-2 infection elicits a robust IgA and IgG response against the N-terminal (N1) and C-terminal (N3) region of the N protein, whereas we failed to detect IgA antibodies and observed a weak IgG response against the disordered linker region (N2) in COVID-19 patients. N and S protein-specific IgG1, IgG2 and IgG3 response was significantly elevated in hospitalized patients with severe disease compared to outpatients with non-severe disease. IgA and total IgG antibody reactivity "],"journal":["Viruses"],"pubmed_title":["Antigen-Specific Antibody Signature Is Associated with COVID-19 Outcome."],"pmcid":["PMC10143282"],"funding_grant_id":["305628/2020-8","2016/00194-8","2266/20","48402179682401","2020/04558-0","2023-2025","062.00967/2020","48401556406778"],"pubmed_authors":["Pinto KR","Nogueira PA","Salgado BB","Forato J","Pereira Filho IV","Correia IS","Carvalho NO","Proenca-Modena JL","Jordao MF","Assuncao EN","Toledo-Teixeira DA","Salgado Sobrinho WB","Melo GC","Sampaio VS","Monteiro WM","Barbosa PP","Souza Neto JN","Cordeiro IB","Lalwani JDB","Granja F","da Silva DSS","Lacerda MVG","Astolfi Filho S","Lalwani P","de Morais TBDN","Souza WM","Dos Santos RO","Val FFA"],"additional_accession":[]},"is_claimable":false,"name":"Antigen-Specific Antibody Signature Is Associated with COVID-19 Outcome.","description":"Numerous studies have focused on inflammation-related markers to understand COVID-19. In this study, we performed a comparative analysis of spike (S) and nucleocapsid (N) protein-specific IgA, total IgG and IgG subclass response in COVID-19 patients and compared this to their disease outcome. We observed that the SARS-CoV-2 infection elicits a robust IgA and IgG response against the N-terminal (N1) and C-terminal (N3) region of the N protein, whereas we failed to detect IgA antibodies and observed a weak IgG response against the disordered linker region (N2) in COVID-19 patients. N and S protein-specific IgG1, IgG2 and IgG3 response was significantly elevated in hospitalized patients with severe disease compared to outpatients with non-severe disease. IgA and total IgG antibody reactivity ","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Apr","modification":"2026-04-07T20:57:40.94Z","creation":"2024-11-12T07:06:55.724Z"},"accession":"S-EPMC10143282","cross_references":{"pubmed":["37112998"],"doi":["10.3390/v15041018"]}}